Autolus announces pricing of public offering (1167351)

Arix Bioscience PLC (ARIX) 
Autolus announces pricing of public offering 
10-Feb-2021 / 09:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 Arix Bioscience plc 
Autolus announces pricing of public offering 
LONDON, 10 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on 
investing in and building breakthrough biotech companies, today announces that its portfolio company, Autolus 
Therapeutics plc ("Autolus", Nasdaq: AUTL), announced the pricing of its underwritten public offering in the United 
States of 14,285,715 American Depositary Shares ("ADSs") representing 14,285,715 ordinary shares, at a public offering 
price of USD7.00 per ADS, for total gross proceeds of approximately USD100.0 million. All ADSs sold in the offering were 
offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 
2,142,857 ADSs at the public offering price, less underwriting discounts and commissions. 
The announcement can be accessed on the Autolus website at https://www.autolus.com/investor-relations/news-and-events/ 
press-releases and full text of the announcement from Autolus is contained below. 
 
[ENDS] 
Enquiries 
For more information on Arix, please contact: 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
[phone] 
[e-mail] 
Optimum Strategic Communications 
Supriya Mathur, Shabnam Bashir 
[phone] 
[e-mail] 
About Arix Bioscience plc 
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech 
companies around cutting-edge advances in life sciences. 
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate 
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth 
phase of our industry to a broader range of investors. www.arixbioscience.com 
 
Autolus Announces Pricing of Public Offering 
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical 
company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public 
offering in the United States of 14,285,715 American Depositary Shares ("ADSs") representing 14,285,715 ordinary shares 
at a public offering price of USD7.00 per ADS, for total gross proceeds of approximately USD100.0 million. All ADSs sold in 
the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up 
to an additional 2,142,857 ADSs at the public offering price, less underwriting discounts and commissions. The offering 
is expected to close on February 12, 2021, subject to customary closing conditions. 
J.P. Morgan and Wells Fargo Securities are acting as joint bookrunners for the offering. Kempen & Co, Mizuho Securities 
and Needham & Company are acting as co-managers. 
The securities are being offered pursuant to an effective shelf registration statement that was previously filed with 
the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement to the prospectus describing the 
terms of the offering was filed with the SEC on February 8, 2021, and a final prospectus supplement will be filed with 
the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of 
the registration statement, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of 
the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European 
Economic Area. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering 
may be obtained for free from either of the joint book-running managers for the offering, J.P. Morgan Securities LLC, c 
/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at [phone] or 
by email at [e-mail]; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 
West 33rd Street, New York, New York, 10001, at [phone] or email a request to [e-mail]. 
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall 
not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be 
unlawful prior to registration or qualification under the securities laws of that jurisdiction. 
About Autolus 
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the 
treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is 
engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize 
cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product 
candidates in development for the treatment of hematological malignancies and solid tumors. 
Forward-Looking Statements 
This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of 
the Private Securities Litigation Reform Act of 1995, including statements with regard to Autolus' expectations 
regarding the completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," 
"intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These 
forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no 
assurance can be given that the proposed securities offering discussed above will be consummated on the terms described 
or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are 
beyond the control of Autolus, including, without limitation, market conditions, failure of customary closing 
conditions and the risk factors and other matters set forth in Autolus' Annual Report on Form 20-F for the year ended 
December 31, 2019 and other filings Autolus makes with the SEC from time to time. Autolus undertakes no obligation to 
publicly update or revise any forward-looking statements, whether as a result of new information, future events or 
otherwise, except as may be required by law. 
Contacts: 
Lucinda Crabtree, Ph.D. 
Vice President, Investor Relations and Corporate Communications 
[phone] 
[e-mail] 
Julia Wilson 
[phone] 
[e-mail] 
Susan A Noonan 
S.A. Noonan Communications, LLC 
[phone] 
[e-mail] 
 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCH 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   93366 
EQS News ID:    1167351 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------ 
 

(END) Dow Jones Newswires

February 10, 2021 04:00 ET (09:00 GMT)